AI
Saudi Arabia
UAE
EgyptQatar Investment Authority Backs $150M Series B for Latigo’s Non-Opioid Pain Breakthrough
2 min
Qatar Investment Authority invested in Latigo Biotherapeutics' $150 million Series B funding round.
The funding will boost Latigo's R&D for non-opioid pain treatments.
Latigo's clinical trials show promising results with LTG-001, a Nav1,8 blocker.
This investment supports safer pain relief amid global opioid addiction concerns.
Investors show strong confidence in Latigo's innovative approach.
Qatar Investment Authority (QIA) has joined a major round of investment into Latigo Biotherapeutics, an American biotech firm intent on tackling pain management without relying on opioid-based medication. The Series B funding brought in an impressive $150 million, with the round led by Blue Owl Capital and boasting a roster of heavyweight investors, including Deep Track Capital, Access Biotechnology, Cormorant Asset Management, and Sanofi Ventures, alongside QIA, Rock Springs Capital, UPMC Enterprises, and Kern Capital.
Several existing backers such as Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Alexandria Venture Investments have also chipped in again, demonstrating their faith in Latigo's cutting-edge approach.
With this substantial infusion of capital, Latigo Biotherapeutics intends to bulk up its research and development capabilities significantly. The company's central mission is developing innovative non-opioid treatments that can tackle pain right at its source, potentially offering a safer alternative for pain-sufferers amid global concerns about opioid addiction and dependency.
Most recently, Latigo proudly announced promising results from the initial phase of clinical trials for its leading candidate, LTG-001. This drug, described as an oral therapy, effectively targets acute pain by selectively blocking Nav1.8 channels, with early findings showing it is both well-tolerated and rapidly absorbed in participants.
It's welcome news indeed for anyone keeping tabs on the opioid epidemic; who among us hasn't come accross stories about the damaging fallout from such painkillers? This fresh round of support from investors including QIA is clearly a vote of confidence in Latigo's vision and could help drive crucial progress toward safer pain relief options for patients everywhere.
As always, Arageek readers, we'll be keeping an eye on developments and sharing updates as this intriguing story unfolds. After all, finding better ways to manage pain without addictive risks isn't just smart science—it's genuinely humane.
